This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Neil Mahapatra is a co-founder of the Oxford Cannabinoid Technologies (OCT) which floated on the LSE in the May this year, he is also founder of UK venture capital business Kingsley Capital Partners (KCP). Oxford Cannabinoid Technologies’ Shares Fall A Further 20% As Chairman Stands Down Following Market Rule Breach.
Based on her data, Dr. Snyder finds that requiring “Total THC” concentrations not to exceed 0.3%, rather than just limiting ?9-THC, The USDA’s October 29, 2019 issuance of the Final Interim Rule (Rule) regarding hemp requires pre-harvest testing to take into account total tetrahydrocannabinol (THC) (Total THC) to determine compliance.
As safety and compliance testing regulations evolve, it will be important to include more than the standard As, Cd, Hg, and Pb to the list of regulated metals. Noncartridge heating methods of cannabis flower and concentrate were compared, and results indicate that the heating device itself is a source of metal contamination.
Big data and technology have become critical to a wide variety of industries in recent years, and the cannabis industry is no exception. Through advanced data collection and the application of sophisticated algorithms, usable data is now available to help marijuana businesses: Predict trends. Met consumer demands. Reduce costs.
The laboratory researched the fine print of every state’s rules for hemp sampling, THC potency, cannabinoid content, residual solvents, pesticides, mycotoxins, heavy metals, and microbiology. With that research, they created elaborate matrices to compare each mandate. Source: [link].
Food and Drug Administration (“FDA”), recently changed guidance on cannabinoids, declaring that all new food products infused with the plant or its derivatives should receive a pre-market approval under the European Union “novel food” regulation. This also applies to extracts of other plants containing cannabinoids.
Let’s take a closer look at five key ways big data and technology are directly impacting the industry. Big Data Streamlines the Marijuana Regulatory Process and Helps Close the Scientific Research Gap. Therefore, the growing marijuana market lacks the clinical data needed to help marijuana businesses create new and better products.
To achieve these purposes, the statute creates a strict legal framework that encompasses both medical and non-medical cannabis in Canada, and prescribes the scope of all permissible products and cannabis-related activities, as well as the offences and penalties for non-compliance. Use of Non-controlled Cannabinoids in Food.
Treasurer Tyler Klimas, Executive Director of the Nevada Cannabis Compliance Board, At-large board member Steve Marks, Executive Director of the Oregon Liquor and Cannabis Board. Public Health and Data Monitoring. Cannabinoid Hemp. Social and Economic Equity. Medical Use and Research. Lab Testing and Product Safety.
The Oregon Liquor Control Commission (OLCC) recently finalized new administrative rules on Delta-8 THC and other artificially derived cannabinoids as directed by HB 3000 (2021). Delta-8 THC and other Artificially Derived Cannabinoids. Artificially Derived Cannabinoids Allowed in SOME Situations.
This export also validates the emergence of the global cannabinoid sector with reliance on quality, traceability and sustainability that Avicanna ’s Aureus products offer. To the knowledge of the Company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.
With Avicanna’s dedication to quality standards and pharmaceutical positioning we are poised to be a significant long-term player in the European medical market that is predominantly focused on medical utility of cannabinoids and where meeting EU pharmacopeia standards are essential.”. New progressive regulation on cannabis in Colombia.
Depending on compliance regulations in other states, producers may use this test for quality assurance purposes prior to testing at a state-licensed laboratory for each state as required. Our analytical data empowers thousands of clients to make informed decisions about product safety and consistency.
NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, and Biopharmaceutical Research Company (“BRC”), a specialty pharmaceutical company that holds federal licenses for importing, analyzing and manufacturing controlled substances in the U.S.,
Building the bridge between brands and the marketplace through testing and the importance of good data. A need for data at all of these levels and data specific to product type drives more advanced methodology in the laboratories, often resulting in a better understanding of the matrix and more accurate data.
The changes place the brunt of the responsibility for child resistance on dispensaries, giving manufacturers and producers until 2020 to get their packaging up to state compliance standards. Cultured Cannabinoids Are On the Way. to begin production on cultured cannabinoids.
In March, last year the US Food and Drug Administration (FDA) requested specific data on liver toxicity data after saying it believed from CBD use posed ‘real risks’ to human health. Data To Be Used In UK . It will allow us to differentiate ourselves from the people that don’t. There are a lot of bad actors in the market.”.
A new report from New Frontier Data delves into the average number of plants that are considered to be “hot” and what the industry could look like in the near future. New Frontier Data released new data on August 5 regarding crops and how many plants have gone “hot,” or exceeded the required limit of less than 0.3 Shutterstock.
Regional economic impact studies provide policymakers, businesses, and community stakeholders with valuable data to inform decision-making, allocate resources, and maximize the positive outcomes associated with the medical marijuana industry’s presence in their respective regions.
And recent data released by the USDA on the value of national hemp production in 2021 reveals that, despite challenges across the country, hemp remains a viable and valuable domestic crop. The USDA is keenly aware of the need for more data from the industry to develop more specific, data-driven policies in the future.
1 Unless otherwise indicated, market share data disclosed in this press release is calculated using the Company’s internal proprietary market share tool that utilizes point of sales data supplied by a third-party data provider, government agencies and our own retail store operations across the country. hemp industry in the U.S.,
This same concept can be used to screen for genetic markers that are associated with specific cannabinoid profiles, physical traits, and pathogen resistance. For example, Oregon CBD analyzed genomic data from a population of autoflower plants to identify a genetic marker for the autoflowering trait.
Medical marijuana refers to the use of cannabis and its cannabinoids to treat medical conditions. This understanding ensures efficient service delivery, compliance with legal requirements, and optimal patient care. The verification processes ensure compliance with state regulations and eligibility criteria.
.” 1 Unless otherwise indicated, market share data disclosed in this press release is calculated using the Company’s internal proprietary market share tool that utilizes point of sales data supplied by a third-party data provider, government agencies and our own retail store operations across the country.
Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Manage on-going compliance requirements, such as licence renewals, registrations, variations, notifications, reports and submission to the regulatory authorities.
Developed and had approved eight rulemaking packages that help streamline application, licensing, and compliance requirements. Launched CannaConnect , a one-stop shop on DCC’s website to help licensees stay in compliance. DCC compliance staff performed more than 3,000 site inspections of licensees.
They did this by building a brand new, state-of-the-art facility using unmatched automation, completely data-driven, able to satisfy the highest throughput and volume, and was designed by implementing and reapplying the proven principles of an ‘assembly line’ process.
Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Manage on-going compliance requirements, such as licence renewals, registrations, variations, notifications, reports and submission to the regulatory authorities.
Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights. and Arjun Chanmugam, M.D.,
Pharmacopeia (USP) issued a statement on delta-8 THC, offering several considerations to help prevent consumer harm resulting from substandard, contaminated or adulterated products containing the cannabinoid. percent on dry weight basis, the content of other cannabinoids or their isomers, such as delta-8 THC, are not explicitly restricted.
4:15-5:00 PM: How Data and Technology can help future policy making: Public Health, Regulatory, and Industry Data Sources. 8:45-10:00 AM: Hemp: Emergence and Proliferation of Novel Cannabinoids – regulatory, health, and market implications. Session Moderator: Tyler Klimas, Executive Director, Nevada Cannabis Compliance Board.
But while THC struggles to reach legitimacy, another cannabinoid walked in without a problem. Some of these companies lace their products with “…synthetic cannabinoids, dangerous chemicals or illegal drugs.”. When that time comes, a lot of businesses will need to watch their compliance. Like in the U.S., No Branding.
Four trade associations have called for revisions to the list of hemp feed products in the EU Catalogue of Feed Materials, and asked for a delay in any decisions regarding the CBD levels for the catalogue’s hemp entries until adequate scientific data is available at the end of 2021. Unaligned reasoning’.
The Association for the Cannabinoid Industry has been launched to lead CBD industry regulation. The Association for the Cannabinoid Industry (ACI) is set to lead the charge for CBD industry regulation. The Association for the Cannabinoid Industry. This announcement represents another key milestone on this path.”.
They are taking issue with the change by the EU in its submission for the term ‘cannabinoids’ states: “Extracts of Cannabis sativa L. and derived products containing cannabinoids are considered novel foods as a history of consumption has not been demonstrated.
Cannabinoids have been shown to inhibit the activity of enzymes that help detoxify chemicals, which can make pesticides more toxic. New Frontier Data CEO Giadha Aguirre de Carcer, pointing to California residue testing results, cites a threat to the medicinal cannabis market. Tell your U.S. Letter to Congress. More at [link].
CBD was flying off the shelves in Austria, as elsewhere in Europe, until the government stepped in recently to effectively outlaw the handling of certain cannabinoid products. it illegal to grow cannabis with the intent to produce the psychoactive cannabinoid THC, Austrians can purchase cannabis seeds and seedlings legally.
Today, HempFusion and its family of brands are one of the select few CBD companies that stand fully prepared to meet or exceed US & global compliance standards. This data provides the necessary safety basis to show that our proprietary hemp extract including CBD is safe for human consumption,” commented Dr. Mitchell.
Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024.
Aguilar has suggested that “cannabis must have similar authorization and use conditions” to those that operate in Spain with products such as morphine and has opened the door for, at one time, community pharmacies -and not just hospital ones- dispense cannabinoid-based products that the Medicines Agency may authorize.
Cannabinoids are the chemical substances found in cannabis. Over 100 different cannabinoids have been linked to the cannabis plant. No data is available regarding prescriptions written in respect of secondary care. What substances are at issue? Pure CBD is not a controlled drug under the Act or the Regulations.
As far as customized medicines are concerned, CBD extracts offer limitless possibilities, as long as the producers are able to control key components like terpene and cannabinoid content beyond CBD or THC. THC Products. . Khiron may have overcome the first regulatory hurtle, but the situation with their THC products is not quite as clear.
Both of these factors, as shown by the data received from countries where legalization has already taken place, very often lead to a reduction in the use of cannabis among young people.
3) Based on the available data, when there is a justified prospect that treatment success (curative or palliative) can be achieved with the medicine in question. As of December 2021, extracts to be used in vaporisers reached the market from Panaxia Labs Israel, and offer an alternative to the pharmacy-prepared oils currently in use.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
98 
Let's personalize your content